[
  {
    "question": "Clavial mass visible from the nostril",
    "option_a": "Chrodmoa",
    "option_b": "Histiocytosis",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Chordomas are rare, malignant bone tumors arising from remnants of the notochord. They typically occur at midline locations such as the clivus (skull base) or sacrum, and a clival chordoma may be visualized endoscopically through the nasal passages. Chordomas exhibit slow growth but are locally aggressive, often causing bone destruction. Histologically, they are characterized by the presence of physaliphorous (bubble\u2011containing) cells. Their midline location makes them distinct from other skull base lesions. Patients with clival chordomas may present with headaches, cranial nerve deficits, or nasal obstruction. In cases where the lesion extends into the nasopharynx, it may be visible from the nostril during an endoscopic exam. Diagnosis is based on imaging with CT (to evaluate bony destruction) and MRI (to assess soft tissue involvement). Differential diagnoses include chondrosarcoma and, less commonly, Langerhans cell histiocytosis, but chordomas typically are midline with a characteristic appearance and histology. The standard treatment is maximal safe surgical resection using approaches that may include endoscopic endonasal surgery, followed by high-dose radiotherapy (proton beam therapy is preferred due to its precision and sparing of surrounding tissues). In pregnancy, surgical intervention is carefully timed (often in the second trimester) and radio-therapy is usually postponed until after delivery; similar caution is applied during lactation with appropriate counseling on treatment timing. Option A (Chordoma) is correct given the clival location and the description of visibility from the nostril. Option B (Histiocytosis) is less likely as it typically involves Langerhans cell histiocytosis, which has a different clinical and imaging profile and is not classically associated with clival masses. 1) Chordomas are midline skull base tumors that can erode the clivus and extend into the nasopharynx. 2) Endoscopic endonasal resection is often the approach of choice. 3) Adjuvant proton therapy is increasingly favored for its targeted delivery and reduced collateral damage. The latest guidelines emphasize a multimodal approach involving surgical resection and adjuvant high-dose proton therapy due to the high local recurrence rate of chordomas. Emerging molecular studies are also investigating potential targeted therapies to improve outcomes.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "HIV/AIDS patients, the most common subtypes of AIDS-associated-",
    "option_a": "EBV-related lymphoma",
    "option_b": "Burkitt\u2019s lymphoma (BL)",
    "option_c": "Large B-cell lymphoma (DLBCL)",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-oncology",
    "explanation": "HIV/AIDS patients have a markedly increased risk of developing lymphoma due to chronic immunosuppression and persistent antigenic stimulation. Among the AIDS\u2010associated lymphomas, aggressive B-cell non-Hodgkin lymphomas are most common, with diffuse large B-cell lymphoma (DLBCL) representing the most frequent subtype. Chronic HIV infection impairs immune surveillance, permitting oncogenic viruses (especially Epstein\u2013Barr virus) and genetic mutations to drive malignant transformation of B cells. DLBCL in this setting often exhibits high proliferation rates and extranodal involvement, and is influenced by the interplay between viral factors and the patient\u2019s immunocompromised status. Patients with HIV/AIDS who develop DLBCL may present with systemic \u201cB symptoms\u201d (fever, night sweats, weight loss) and may also have extranodal manifestations (such as involvement of the CNS, gastrointestinal tract, or bone marrow). The aggressive nature of DLBCL can lead to rapidly enlarging masses and varied clinical presentations. Diagnosis is established with tissue biopsy and immunohistochemical staining. Imaging (CT, PET-CT) is used for staging, while differentiating DLBCL from other AIDS-related lymphomas (e.g., Burkitt\u2019s lymphoma, plasmablastic lymphoma) relies on histologic criteria, proliferation indices, and viral studies. The mainstay of treatment is combination chemotherapy (e.g., CHOP regimen with the addition of rituximab when the tumor expresses CD20) administered concurrently with optimized antiretroviral therapy. In pregnancy and lactation, chemotherapy regimens carry risks of teratogenicity and require multidisciplinary planning to balance maternal benefit with fetal risks. Close monitoring and modified dosing are indicated where necessary. Option A (EBV-related lymphoma) recognizes the role of EBV in the pathogenetic process, but does not denote a specific subtype. Option B (Burkitt\u2019s lymphoma) is indeed seen in AIDS patients, particularly in children and in endemic areas, but overall DLBCL is more common. Option C (Large B-cell lymphoma [DLBCL]) is the correct answer as it represents the most frequently encountered AIDS-associated lymphoma subtype. 1. DLBCL is the most common AIDS-associated lymphoma. 2. The interplay between HIV, EBV, and immunosuppression predisposes to aggressive B-cell neoplasms. 3. Treatment involves combined chemotherapy and antiretroviral therapy with special considerations in pregnancy due to teratogenic risks of chemotherapeutic agents. Recent studies underline the improved survival outcomes with the concurrent use of antiretroviral therapy and tailored chemoimmunotherapy (including rituximab) in HIV-positive patients with DLBCL. Ongoing research is exploring targeted agents and immunotherapies that may further improve outcomes in this high-risk population.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Patient with left side chronic headache developed UE weakness, found to have on imaging a mass with a dural tail. Where is the mass location",
    "option_a": "olfactory groove meningioma",
    "option_b": "Parasagittal meningioma",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "HIV/AIDS patients have a markedly increased risk of developing lymphoma due to chronic immunosuppression and persistent antigenic stimulation. Among the AIDS\u2010associated lymphomas, aggressive B-cell non-Hodgkin lymphomas are most common, with diffuse large B-cell lymphoma (DLBCL) representing the most frequent subtype. Chronic HIV infection impairs immune surveillance, permitting oncogenic viruses (especially Epstein\u2013Barr virus) and genetic mutations to drive malignant transformation of B cells. DLBCL in this setting often exhibits high proliferation rates and extranodal involvement, and is influenced by the interplay between viral factors and the patient\u2019s immunocompromised status. Patients with HIV/AIDS who develop DLBCL may present with systemic \u201cB symptoms\u201d (fever, night sweats, weight loss) and may also have extranodal manifestations (such as involvement of the CNS, gastrointestinal tract, or bone marrow). The aggressive nature of DLBCL can lead to rapidly enlarging masses and varied clinical presentations. Diagnosis is established with tissue biopsy and immunohistochemical staining. Imaging (CT, PET-CT) is used for staging, while differentiating DLBCL from other AIDS-related lymphomas (e.g., Burkitt\u2019s lymphoma, plasmablastic lymphoma) relies on histologic criteria, proliferation indices, and viral studies. The mainstay of treatment is combination chemotherapy (e.g., CHOP regimen with the addition of rituximab when the tumor expresses CD20) administered concurrently with optimized antiretroviral therapy. In pregnancy and lactation, chemotherapy regimens carry risks of teratogenicity and require multidisciplinary planning to balance maternal benefit with fetal risks. Close monitoring and modified dosing are indicated where necessary. Option A (EBV-related lymphoma) recognizes the role of EBV in the pathogenetic process, but does not denote a specific subtype. Option B (Burkitt\u2019s lymphoma) is indeed seen in AIDS patients, particularly in children and in endemic areas, but overall DLBCL is more common. Option C (Large B-cell lymphoma [DLBCL]) is the correct answer as it represents the most frequently encountered AIDS-associated lymphoma subtype. 1. DLBCL is the most common AIDS-associated lymphoma. 2. The interplay between HIV, EBV, and immunosuppression predisposes to aggressive B-cell neoplasms. 3. Treatment involves combined chemotherapy and antiretroviral therapy with special considerations in pregnancy due to teratogenic risks of chemotherapeutic agents. Recent studies underline the improved survival outcomes with the concurrent use of antiretroviral therapy and tailored chemoimmunotherapy (including rituximab) in HIV-positive patients with DLBCL. Ongoing research is exploring targeted agents and immunotherapies that may further improve outcomes in this high-risk population.",
    "exam_year": "2023",
    "exam_type": "Part II"
  },
  {
    "question": "Elderly patient diagnosed with GBM and was treated 5 years ago, presented with decrease level of consciousness, MRI brain attached showed tumor with vasogenic edema, what is next step?",
    "option_a": "Steroid",
    "option_b": "Temozolomide",
    "option_c": "Radiation",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "In patients with glioblastoma multiforme (GBM), vasogenic edema is a common complication due to breakdown of the blood\u2013brain barrier, leading to fluid leakage into the brain parenchyma. The use of corticosteroids, such as dexamethasone, is the cornerstone of managing this edema to promptly reduce intracranial pressure, especially when clinical deterioration (e.g., decreased level of consciousness) is evident. GBM disrupts the integrity of the blood\u2013brain barrier, resulting in vasogenic edema marked by the accumulation of plasma proteins and water in the extracellular space. This edema contributes to increased intracranial pressure causing neurological symptoms. Corticosteroids help stabilize the capillary membranes reducing the fluid leakage and cerebral swelling. An elderly patient with a history of treated GBM, now presenting with decreased consciousness and MRI findings of tumor recurrence with vasogenic edema, is most likely experiencing symptoms from raised intracranial pressure. The administration of steroids is aimed at quickly reducing the edema, thereby alleviating symptoms and preventing further neurological injury. The diagnosis is established based on imaging modalities such as MRI, which reveal tumor recurrence along with significant peritumoral vasogenic edema. Differential diagnoses include post-treatment changes like radiation necrosis or pseudoprogression, but the clinical scenario of acute deterioration favors active edema requiring urgent treatment. Immediate management focuses on reducing intracranial pressure. High-dose corticosteroids (typically dexamethasone) are used to rapidly decrease vasogenic edema. While long-term tumor control is managed with chemotherapy (e.g., temozolomide) and radiation therapy, these modalities do not provide the rapid symptomatic relief required in emergencies. In pregnant or lactating patients, corticosteroid use should be guided by a risk-benefit analysis: dexamethasone is FDA category C but may be used when maternal benefit justifies potential fetal risks, with careful monitoring and consultation with obstetric and neonatology services. Option A (Steroid) is appropriate as it provides immediate symptomatic relief by reducing vasogenic edema. Option B (Temozolomide) is primarily a chemotherapeutic agent used as an adjuvant in GBM treatment, and its effects are not immediate. Option C (Radiation) is indicated for long-term management of tumor progression but does not rapidly alleviate life-threatening edema. Option D is ambiguous and is not contributing to the immediate management strategy. Immediate administration of high-dose steroids can markedly improve neurological function in patients with peritumoral edema. Always monitor for steroid-related side effects such as hyperglycemia and immunosuppression. In individuals with special circumstances, including pregnancy or lactation, involve a multidisciplinary team to balance the benefits with potential risks. Recent guidelines and clinical studies consistently affirm the use of dexamethasone for rapid reduction of vasogenic edema in high-grade gliomas. The evidence supports that prompt steroid administration can lead to significant neurological improvement, justifying its use as the first line in emergent situations, including in special patient populations where careful risk assessment is warranted.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Child with neurofibromatosis, headache and syncope found to have tumor in the lateral ventricular, what is the most likely diagnosis?",
    "option_a": "Subependymoma",
    "option_b": "Central neurocytoma",
    "option_c": "Choroid plexus",
    "option_d": "",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-oncology",
    "explanation": "In pediatric patients with an intraventricular mass, the most common tumor encountered in the lateral ventricle is a choroid plexus tumor (usually a papilloma). These lesions can cause symptoms such as headache and syncope primarily due to CSF overproduction and/or obstruction leading to increased intracranial pressure. Although neurofibromatosis (especially NF2) is classically associated with other CNS tumors (e.g., schwannomas, meningiomas, and ependymomas), in the context of a lateral ventricular tumor in a child, a choroid plexus tumor fits best. Choroid plexus papillomas arise from the epithelial cells that line the choroid plexus. They are benign papillary proliferations that can produce excess cerebrospinal fluid, resulting in hydrocephalus. The increased intracranial pressure from hydrocephalus then manifests as headache, syncope, and other signs of raised intracranial pressure. A child presenting with headache and syncope who is found to have an intraventricular mass on imaging should prompt consideration of tumors that commonly affect that age group. In this case, the lateral ventricular location strongly suggests a choroid plexus papilloma. The presence of neurofibromatosis may raise awareness for multiple CNS tumors, but among the given options, the choroid plexus tumor is most consistent with the patient\u2019s age, symptoms, and tumor location. The diagnosis typically starts with neuroimaging. CT scans may reveal an enhancing lesion within the lateral ventricle, and MRI can further delineate the tumor\u2019s characteristics and its relationship to CSF pathways. Differential diagnoses include central neurocytoma (which is more common in young adults), and subependymoma (usually seen in older adults). Histologic examination after surgical resection confirms the diagnosis. Although neurofibromatosis raises the possibility of other tumors, the location and patient\u2019s age limit the main differential to choroid plexus tumors in this scenario. The mainstay of treatment for choroid plexus papilloma is complete surgical resection. This both alleviates hydrocephalus and secures a histological diagnosis. In cases where hydrocephalus is severe, temporary CSF diversion (e.g., external ventricular drain) may be necessary. For patients who are pregnant or lactating, multidisciplinary management is essential. In pregnancy, if surgical intervention is required urgently due to deteriorating neurological status, neurosurgical teams will coordinate with obstetricians to optimize fetal outcomes. Elective surgeries may be timed carefully according to gestational age. During lactation, anesthetic and postoperative medications should be selected to minimize transmission in breast milk, following the latest guidelines for safety. Option A (Subependymoma) is generally a slow-growing tumor occurring in older patients and is typically discovered incidentally. Option B (Central Neurocytoma) is seen in young adults and usually localizes near the foramen of Monro, making it less likely in a child. Option C (Choroid Plexus Tumor), which in context likely refers to choroid plexus papilloma, is the most common intraventricular tumor in children and fits the clinical scenario. Option D is absent; hence, the best answer is Option C. \u2022 In children with intraventricular masses, always consider choroid plexus papilloma, particularly when signs of increased intracranial pressure (headache, syncope) are present. \n\u2022 Although neurofibromatosis is associated with multiple CNS tumors, tumor location and patient age help narrow the differential diagnosis. \n\u2022 Complete surgical resection is both diagnostic and therapeutic. Recent studies and clinical guidelines continue to support surgical resection as the treatment of choice for choroid plexus papilloma, as it provides symptomatic relief by resolving hydrocephalus and allows for a definitive tissue diagnosis. In pregnant and lactating patients, current guidelines emphasize a cautious, individualized approach that balances the risks of anesthesia and surgery with the potential for rapid neurologic deterioration.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient presented with lethargy and unilateral weakness MRI brain attached showed tumor crossing midline with necrotic features and mass effect, what is the diagnosis? (GBM picture)",
    "option_a": "Grade 2 glioma",
    "option_b": "Grade 4 glioma",
    "option_c": "Meningioma",
    "option_d": "? (benign tumor)",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Glioblastoma multiforme (GBM) is a highly aggressive primary brain tumor, classified as a Grade IV glioma. It is notorious for its rapid growth, tendency to necrose, and capacity to cross the midline, often producing a 'butterfly' appearance. GBM exhibits rapid cellular proliferation, marked angiogenesis, and areas of necrosis with pseudopalisading cells. The tumor\u2019s infiltrative behavior, high mitotic activity, and resistance to apoptosis contribute to its aggressive nature. Patients often present with progressive neurological deficits such as weakness, altered mental status, and headaches. The necrotic and hemorrhagic components along with mass effect on imaging are classic features. The crossing of the midline is a distinguishing radiologic sign suggesting a GBM rather than lower-grade gliomas. Diagnosis is based on neuroimaging\u2014contrast-enhanced MRI typically reveals irregular ring-enhancing lesions with central necrosis\u2014and confirmed by tissue biopsy. Differential diagnoses include metastatic lesions, anaplastic astrocytomas, and primary central nervous system lymphomas; however, the rapid progression and radiologic features help differentiate GBM. The standard treatment involves maximal safe surgical resection followed by adjuvant radiotherapy with concurrent and adjuvant temozolomide chemotherapy (Stupp protocol). For patients who are pregnant, treatment modifications are necessary to balance maternal and fetal risks\u2014surgery can be safely performed, but radiotherapy and chemotherapy require careful planning and often delay until postpartum if feasible. Option B (Grade 4 glioma) is correct as it best describes GBM with its classic imaging features of necrosis, mass effect, and midline crossing. Option A (Grade 2 glioma) does not fit the aggressive radiologic presentation. Option C (Meningioma) is usually benign and rarely presents with necrosis or rapid progression, and Option D is inconsistent with the findings. 1) GBM is the most common primary malignant brain tumor in adults. 2) Key imaging features include ring enhancement and central necrosis. 3) The classic 'butterfly' appearance due to midline crossing is highly suggestive of GBM. Recent research continues to explore targeted therapies and immunotherapies for GBM. However, the Stupp protocol remains the gold standard with ongoing studies investigating genetic and molecular markers to better stratify treatment outcomes.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "In male patient with metastatic cancer exclusive to skull (or dura) and unknown origin of cancer, what should be done?",
    "option_a": "CT chest",
    "option_b": "Pelvic MRI",
    "option_c": "Abdomen MRI",
    "option_d": "?",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "In cases of metastatic cancer involving the skull or dura with an unknown primary source, identifying the primary tumor is critical. In men, lung cancer is one of the most common sources of metastasis to the skull and dura. Metastatic lesions occur when cancer cells disseminate via the bloodstream and seed distant sites. The skull and dura can be involved due to rich vascular supply. In males, lung cancer is a frequent culprit because of its high metastatic potential and prevalence. A male patient with metastatic lesions confined to the skull or dura and no known primary tumor should raise a high index of suspicion for a lung primary, among other possibilities. The clinical workup is aimed at identifying the primary site to tailor the appropriate systemic therapy. The initial evaluation typically includes imaging studies starting with a CT scan of the chest, as lung cancer is common in this demographic. Depending on initial results, further imaging of the abdomen, pelvis, or a whole-body PET-CT might be warranted. Differential diagnoses include metastases from prostate cancer or other less common primaries; however, lung lesions are most common in men. Once metastasis is identified, the management includes a thorough systemic workup. For a male with suspected lung origin, a CT chest is the first-line investigation. In pregnancy or lactation, imaging studies must balance fetal radiation exposure; MRI or ultrasound may be preferred when safe, though CT can be used with proper shielding if necessary. Option A (CT chest) is correct because it targets the most likely primary site in males with skull/dural metastases. Option B (Pelvic MRI) and Option C (Abdomen MRI) are less relevant as first-line tests in this context given the epidemiology of metastatic disease in men. 1) In men, lung cancer is the most likely primary site in cases of metastatic skull/dural lesions. 2) A systematic, step-wise imaging workup is essential in carcinoma of unknown primary. 3) Consider radiation safety in imaging studies during pregnancy. Current guidelines stress the use of appropriate imaging (often starting with CT chest) in the evaluation of metastatic lesions of unknown primary origin, and emerging data support PET-CT for further evaluation when initial imaging is inconclusive.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "A 50 year-old lady with dizziness, sensorineural hearing loss and nystagmus found to have brain tumor on MRI brain originate from pons near 4th ventricle (Cerebellopontine angle syndrome)",
    "option_a": "Schwannoma",
    "option_b": "Ependymoma",
    "option_c": "Meningioma",
    "option_d": "? (Maybe Medulloblastoma)",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Cerebellopontine angle (CPA) syndrome typically presents with symptoms such as sensorineural hearing loss, tinnitus, and balance disturbances. Vestibular schwannoma (acoustic neuroma) is the most common lesion in the CPA and is a benign tumor arising from Schwann cells of the vestibulocochlear nerve (CN VIII). Vestibular schwannomas develop from the myelin-forming Schwann cells and lead to progressive compression of the cranial nerves in the CPA. The tumor\u2019s growth results in symptoms from nerve compression including sensorineural hearing loss, dizziness, and nystagmus. Although typically benign, the tumor can cause significant morbidity due to its location near critical brainstem structures. In a 50-year-old female presenting with dizziness, sensorineural hearing loss, and nystagmus, the clinical picture is most consistent with a vestibular schwannoma. The imaging finding of a mass in the CPA further supports this diagnosis. Despite the question\u2019s wording about 'originating from the pons near the 4th ventricle,' the constellation of symptoms is classic for a schwannoma affecting the vestibulocochlear nerve. MRI with gadolinium contrast is the diagnostic modality of choice to evaluate CPA lesions. Differential diagnoses include meningiomas, which also occur in the CPA but have different imaging characteristics, and less commonly ependymomas or medulloblastomas, which are more typical in pediatric populations or arise from other neural structures. Management depends on tumor size, patient symptoms, and overall health. For small, asymptomatic tumors, observation with serial imaging is acceptable. For symptomatic lesions or those with significant growth, treatment options include stereotactic radiosurgery or microsurgical resection. In pregnant patients, conservative management is often preferred until after delivery unless there is rapid tumor growth or life-threatening symptoms. Option A (Schwannoma) is correct because it aligns with the patient\u2019s clinical presentation and imaging findings in the CPA region. Option B (Ependymoma) typically arises within the fourth ventricle in children, Option C (Meningioma) is a differential but less likely with classic sensorineural hearing loss, and Option D (Medulloblastoma) is a pediatric malignancy not consistent with the presentation. 1) Vestibular schwannoma is the most common CPA tumor, particularly presenting with sensorineural hearing loss. 2) MRI is the gold standard for diagnosing CPA lesions. 3) Management options vary from observation to surgical resection based on symptoms and tumor size. Recent advances focus on less invasive management strategies such as stereotactic radiosurgery, especially for small to moderate-sized tumors, with an emphasis on hearing preservation. Ongoing studies continue to optimize treatment protocols in the context of patient-specific factors, including in special populations such as pregnant women.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "Patient presented with tinnitus, hearing loss and was found to have tumor in pons near the fourth ventricle\nMost likely origin of tumor?",
    "option_a": "Shwannoma",
    "option_b": "Ependymoma",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "This question describes a patient with tinnitus and hearing loss \u2013 classic presenting symptoms of an acoustic neuroma (vestibular schwannoma). These tumors arise from the Schwann cells of the vestibulocochlear nerve (CN VIII) and are most typically located in the cerebellopontine angle. Although the description mentions a tumor in the pons near the fourth ventricle, the clinical picture of sensorineural hearing loss and tinnitus is most consistent with a schwannoma related to CN VIII. Schwannomas are benign, slow-growing nerve sheath tumors that develop from Schwann cells. In the case of vestibular schwannomas, the growth leads to compression of the vestibulocochlear nerve fibers, resulting in gradual hearing loss, tinnitus, and sometimes balance issues. The tumor\u2019s location in the cerebellopontine angle can also affect nearby brainstem structures, though the predominant symptoms reflect cranial nerve VIII involvement. Patients typically present with unilateral sensorineural hearing loss, tinnitus, and possibly imbalance. The tumor, although benign, can progressively compress adjacent structures. The mismatch between the described location (pons near the fourth ventricle) and the symptom set highlights the importance of correlating clinical findings with imaging. In practice, a lesion causing these symptoms in the region would be evaluated with high-resolution MRI focused on the cerebellopontine angle. Magnetic Resonance Imaging (MRI) with gadolinium contrast is the gold standard to visualize the tumor and assess its size and precise location. Differential diagnoses include meningioma, epidermoid cyst, and rarely other brainstem gliomas. The clinical correlation with unilateral auditory symptoms helps distinguish vestibular schwannoma from other CPA masses. Management includes observation for small, asymptomatic tumors; stereotactic radiosurgery (e.g., Gamma Knife) is often considered for small to medium-sized tumors; and microsurgical resection is used in larger tumors or when there is significant brainstem compression. In pregnancy, management is usually conservative with careful observation because surgery and radiotherapy carry risks for both the mother and the fetus. Lactation considerations are similar, requiring careful planning around timing of interventions and potential effects of anesthesia and medications. Option A (Schwannoma) is correct because the clinical presentation of tinnitus and hearing loss is most consistent with an acoustic (vestibular) schwannoma. Option B (Ependymoma) is less likely because ependymomas arise from ependymal cells lining the ventricles (commonly the fourth ventricle in children) and typically do not present with auditory symptoms. 1. Tinnitus and unilateral sensorineural hearing loss in adults are hallmark signs of vestibular schwannoma. 2. A key imaging feature is the location in the cerebellopontine angle, which may sometimes be misdescribed anatomically. Recent guidelines favor observation or radiosurgery for small to moderate-sized vestibular schwannomas, especially when hearing is still preserved. Advances in imaging and minimally invasive surgical techniques have improved outcomes, with current research emphasizing the importance of individualized management plans based on tumor size, hearing status, and patient age.",
    "exam_year": "2024",
    "exam_type": "Part II"
  },
  {
    "question": "6-year-old girl has headache and diplopia. On examination, she has impaired upward gaze, lid retraction, and convergence retraction nystagmus. What is the diagnosis?",
    "option_a": "Pinealoma",
    "option_b": "Medulloblastoma",
    "option_c": "Oligodendroglioma",
    "option_d": "Vestibular schwannoma",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "The clinical picture in this case \u2013 a 6-year-old girl with headache, diplopia, impaired upward gaze, lid retraction, and convergence-retraction nystagmus \u2013 is highly characteristic of Parinaud syndrome. This syndrome is most commonly associated with pineal region tumors, such as pinealomas, which compress the dorsal midbrain. Pineal tumors, including pinealomas, exert pressure on the dorsal midbrain, particularly the pretectal area, disrupting vertical gaze pathways and eliciting Parinaud syndrome. Impaired upward gaze, along with the distinctive convergence-retraction nystagmus, results from dysfunction in the vertical gaze center and its neural connections. The features of Parinaud syndrome (including impaired upward gaze and pupillary abnormalities such as lid retraction) correlate with involvement of the midbrain structures adjacent to the pineal gland. The occurrence of headache and diplopia further supports raised intracranial pressure and a mass effect in the pineal region. The evaluation begins with neuroimaging \u2013 preferably an MRI of the brain with focus on the pineal region \u2013 to identify the tumor. Differential diagnoses include germinoma, pineocytoma, and non-germinomatous germ cell tumors; additionally, other causes of dorsal midbrain syndrome should be considered. The age of the patient adds further suspicion for a pineal region neoplasm. Management typically involves neurosurgical evaluation. For resectable tumors, surgical removal is considered first-line. Adjuvant therapies such as radiotherapy and/or chemotherapy may be warranted for malignant or unresectable tumors. In pediatric patients, treatment must be judicious to preserve neurological function. For pregnant or lactating patients (though less common in this age group), treatment planning involves multidisciplinary input with careful consideration of fetal/neonatal risks if imaging is required or if surgical intervention is necessary. Option A (Pinealoma) is correct due to the classic presentation of Parinaud syndrome associated with pineal region masses. Option B (Medulloblastoma), Option C (Oligodendroglioma), and Option D (Vestibular schwannoma) do not typically produce the constellation of symptoms seen here and are unlikely to cause isolated dorsal midbrain signs. 1. Parinaud syndrome is a classic sign of dorsal midbrain involvement, especially due to pineal region tumors. 2. In children presenting with these ocular findings and headache, a pinealoma or related tumor should be high on the differential. Current management of pineal region tumors involves multidisciplinary approaches with neurosurgery, neuro-oncology, and radiation oncology; studies are ongoing to optimize treatment protocols in pediatric populations with considerations to long-term cognitive outcomes.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Child present with CP angle tumor and hearing loss for more than 5 months what to do:",
    "option_a": "Schedule him for elective surgery",
    "option_b": "Urgent spine MRI and Send for genetic test",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "A cerebellopontine (CP) angle tumor in a child with a prolonged history of hearing loss raises significant suspicion for a genetic syndrome, particularly Neurofibromatosis Type 2 (NF2). NF2 is known for causing bilateral vestibular schwannomas along with other CNS tumors. Hence, a comprehensive workup is indicated rather than immediate surgical intervention. NF2 is an autosomal dominant disorder caused by mutations in the NF2 gene, which encodes the tumor suppressor protein merlin. Loss of function leads to the development of multiple benign tumors, including vestibular schwannomas, meningiomas, and ependymomas. The CP angle lesion and associated hearing loss are classic for vestibular schwannoma in the setting of NF2. In children, the occurrence of a CP angle tumor combined with hearing loss (especially if the onset is insidious over several months) strongly suggests NF2, which often presents with multiple lesions. It is crucial to perform a thorough evaluation for other associated tumors, including those along the spinal cord, which may be asymptomatic initially. Beyond brain imaging (MRI with gadolinium), a spinal MRI is important to detect other lesions such as spinal ependymomas or meningiomas associated with NF2. Genetic testing for mutations in the NF2 gene confirms the diagnosis. Differential diagnoses include isolated vestibular schwannoma, which is rare in the pediatric population, or other CPA masses that do not have a genetic association. Initial management should focus on complete evaluation and genetic confirmation. Elective surgical intervention for the CP angle tumor is considered only after thorough imaging (including a spine MRI) and genetic counseling. Management options include surveillance, microsurgical resection, and stereotactic radiosurgery depending on tumor size and progression. For pregnant patients, the timing of intervention is critical \u2013 if the tumor is stable, intervention may be postponed until after delivery, with careful interdisciplinary management during pregnancy and lactation. Option B (Urgent spine MRI and send for genetic test) is correct. Elective surgery (Option A) would be premature without a full staging workup, as NF2 may involve multiple lesions that need to be delineated before any intervention is planned. Options C and D are not provided or are irrelevant to the described scenario. 1. In pediatric patients, the presence of a CP angle tumor with hearing loss should prompt evaluation for NF2. 2. A complete workup including spinal imaging and genetic testing is critical before any surgical intervention. Recent guidelines emphasize early and comprehensive evaluation for NF2 in children presenting with CP angle tumors. Advances in genetic testing and whole-body MRI protocols have improved early diagnosis and guided tailored management strategies, with a trend towards conservative management when feasible.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Most common benign intracranial neoplasm:",
    "option_a": "Meningioma",
    "option_b": "GBM",
    "option_c": "Pituitary adenoma",
    "option_d": "Schwannoma",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Meningiomas are the most common benign intracranial neoplasms. They originate from the arachnoid cap cells of the meninges and typically present as extra-axial masses in adults, frequently discovered incidentally or when they exert mass effect on adjacent structures. Meningiomas are generally slow-growing, benign tumors (WHO Grade I in most cases). Their pathogenesis involves the proliferation of arachnoidal cells, sometimes influenced by hormonal factors (notably progesterone receptors, particularly in females), and they may show a characteristic 'dural tail' on imaging due to reactive changes in the adjacent dura. Clinically, meningiomas often present with symptoms related to mass effect, including headache, seizures, or focal neurological deficits depending on their location. Their benign nature typically allows for gradual symptom onset, and many are discovered incidentally during imaging for unrelated reasons. Diagnosis is usually confirmed with MRI of the brain with contrast, which shows a well-circumscribed, dural-based lesion with homogeneous enhancement and, often, a dural tail sign. Differential diagnoses include schwannomas, pituitary adenomas, and other dural-based lesions such as metastases. Distinguishing features on imaging and clinical presentation help in differentiating these entities. Management is guided by the size, location, and symptomatology of the tumor. Asymptomatic meningiomas may be monitored with serial imaging. Symptomatic lesions, or those showing growth, are typically managed with surgical resection, which is often curative for benign tumors. Radiosurgery is an option for small or surgically inaccessible meningiomas or for residual disease post-surgery. In pregnant patients, if the meningioma is asymptomatic or slow-growing, conservative management or postponement of surgery until postpartum may be considered, while symptomatic lesions may require intervention with multidisciplinary risk-benefit assessment. Lactating patients are managed similarly, with attention to the minimal interference with breastfeeding. Option A (Meningioma) is correct. Option B (GBM) is incorrect as glioblastoma multiforme is a highly malignant tumor. Option C (Pituitary adenoma) and Option D (Schwannoma) are also benign but occur less frequently as overall intracranial neoplasms compared to meningiomas when considering all primary brain tumors. 1. Meningiomas are highly prevalent in middle-aged females and may be hormonally influenced. 2. The 'dural tail' sign on MRI is a useful imaging clue for meningiomas, although it is not pathognomonic. Recent studies have refined the management of meningiomas with emphasis on individualized treatment plans, balancing surgical risks versus observation for asymptomatic lesions. Advances in stereotactic radiosurgery and improved imaging techniques have contributed to better outcomes and quality of life, with ongoing research into the molecular genetics of these tumors offering future therapeutic targets.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Common child posterior fossa tumor:",
    "option_a": "Ependymoma, astrocytoma and medulloblastoma",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Posterior fossa tumors in children typically involve neoplasms arising in the cerebellum and its surrounding structures. The most common pediatric tumors in this region include medulloblastoma, juvenile pilocytic astrocytoma (a variant of astrocytoma), and ependymoma. These tumors are important because they often lead to signs of raised intracranial pressure due to their location near the fourth ventricle. Medulloblastomas are aggressive, highly malignant embryonal tumors arising in the cerebellar vermis. Juvenile pilocytic astrocytomas (a subtype of astrocytoma seen in children) are typically circumscribed and have a benign behavior, though location may hamper complete resection. Ependymomas originate from the ependymal lining of the ventricles and may cause obstructive hydrocephalus. Their growth patterns, cellular origins, and propensity for local spread are based on underlying molecular and genetic processes which continue to be refined with current research. Children with posterior fossa tumors often present with symptoms related to increased intracranial pressure such as headache, nausea, and vomiting, along with cerebellar signs such as ataxia. The location of the tumor (for example, midline involvement in medulloblastoma) correlates with balance and coordination deficits, while ependymomas may directly obstruct CSF outflow leading to hydrocephalus. The diagnostic evaluation typically begins with neuroimaging\u2014magnetic resonance imaging (MRI) of the brain is the modality of choice to delineate tumor location, extent, and characteristics. Differential diagnoses include brainstem gliomas and rare cerebellar tumors, but features on MRI can help differentiate based on enhancement patterns, location, and involvement of adjacent structures. Management is typically multi-modal. For medulloblastoma, the first-line treatment is maximal safe surgical resection followed by adjuvant therapy (craniospinal radiation and chemotherapy), tailored by risk stratification. For juvenile pilocytic astrocytoma and ependymoma, gross total resection is the goal when feasible. In pediatric patients, potential long-term neurocognitive effects of radiotherapy are carefully weighed, and protocols are designed to minimize toxicity. While pregnancy and lactation considerations are not applicable to a pediatric population, in general, for young patients who are pregnant or lactating, modifications in radiotherapy dosing and chemotherapy regimens are considered to reduce fetal or neonatal exposure. Option A lists ependymoma, astrocytoma (typically referring to juvenile pilocytic astrocytoma in children), and medulloblastoma, which together represent the classic trio of common posterior fossa tumors in children. The other options are blank, so Option A is correct. 1. Posterior fossa tumors in children often present with hydrocephalus secondary to fourth ventricular obstruction. 2. The age of the patient and the tumor location (vermis versus cerebellar hemispheres) can hint at the tumor type. 3. Advances in molecular classification have improved risk stratification, particularly for medulloblastoma. Recent research emphasizes the role of molecular markers and genetic profiling in these tumors, which has been integrated into the latest WHO classification. These insights guide tailored treatment protocols that aim to maximize disease control while minimizing treatment-related toxicities.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "4-year-old child with nausea, vomiting, diplopia and ataxia. Diagnosis:",
    "option_a": "Craniopharyngioma",
    "option_b": "Medulloblastoma",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Medulloblastoma is the most common malignant brain tumor in children. Its typical location in the cerebellar vermis explains the constellation of symptoms related to balance and coordination, as well as increased intracranial pressure. Medulloblastomas arise from primitive neuroectodermal cells in the cerebellum and grow rapidly. Their location near the fourth ventricle predisposes patients to obstructive hydrocephalus, leading to increased intracranial pressure. This tumor is also characterised by its potential for cerebrospinal fluid dissemination. A 4-year-old child presenting with nausea, vomiting, diplopia, and ataxia fits the clinical picture of a posterior fossa lesion. The nausea and vomiting are attributable to raised intracranial pressure, while diplopia and ataxia arise from cerebellar involvement. Craniopharyngiomas, in contrast, are typically suprasellar and present with endocrine dysfunction and visual field deficits. The work-up includes neuroimaging, with MRI being the gold standard to delineate the tumor\u2019s location, extent, and its effect on adjacent structures. Differential diagnoses include ependymoma and cerebellar astrocytoma; however, their imaging characteristics and clinical presentations differ (e.g., location in the cerebellar hemispheres vs. vermis). The cornerstone of treatment is maximal safe surgical resection followed by adjuvant therapy. For children older than 3 years, craniospinal irradiation is standard when risk-adapted, followed by chemotherapy. In cases where radiation is delayed or modified, especially in very young or vulnerable patients, careful adjustment is required. While pregnancy and lactation considerations are not relevant in a 4-year-old, similar principles in adult cases involve delaying or modifying radiotherapy and chemotherapy to protect the fetus or infant. Option A (Craniopharyngioma) is incorrect because it typically presents with endocrine abnormalities and vision loss due to its suprasellar location. Option B (Medulloblastoma) accurately reflects the diagnosis in a child with the described symptoms. Options C and D are not provided, making Option B the correct choice. 1. Medulloblastoma often presents with truncal ataxia due to vermian involvement. 2. Signs of increased intracranial pressure (headache, nausea, vomiting) are common. 3. Early surgical resection improves prognosis and guides further therapy. Recent studies have underscored the importance of molecular subclassification of medulloblastoma, which helps tailor adjuvant therapy. Contemporary protocols aim to balance effective treatment against long-term neurotoxicity, particularly in the pediatric population.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Diffuse astrocytoma grade 2:",
    "option_a": "Most common type is poly astrocytoma",
    "option_b": "Surgical removal has good outcome.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Diffuse astrocytoma Grade II is a type of low-grade glioma that is infiltrative in nature. These tumors are most often seen in young adults and can present with seizures and focal neurological deficits. They differ from circumscribed gliomas (such as pilocytic astrocytoma) given their tendency to invade surrounding brain tissue. Diffuse astrocytomas are characterized by slow growth but infiltrative margins, making complete surgical removal challenging. Although they are considered low grade (WHO Grade II), these tumors retain the risk for malignant transformation over time. Their behavior is partly dictated by molecular markers such as IDH mutation status and 1p/19q codeletion (the latter more typical of oligodendrogliomas). Patients often present with seizures or subtle cognitive and focal deficits rather than signs of acute intracranial hypertension. The tumor\u2019s infiltrative character means that even when surgical resection is performed, microscopic residual disease may persist, contributing to eventual recurrence. Magnetic resonance imaging (MRI) with T2/FLAIR sequences is essential in identifying the diffuse, poorly defined margins of these tumors. Differential diagnoses include oligodendrogliomas (which may show calcifications and a \u2018fried egg\u2019 appearance histologically) and other low-grade gliomas. Biopsy and molecular studies are important to confirm the diagnosis and to guide treatment. The primary treatment is maximal safe surgical resection. Gross total resection, when achievable, is associated with prolonged progression\u2010free survival. In cases with subtotal resection or progression, adjuvant therapies, including radiotherapy (with careful consideration of neurotoxicity) and chemotherapy (e.g., temozolomide), may be employed. In adult women who are pregnant or lactating, both radiotherapy and chemotherapy require careful modification; typically, radiotherapy is deferred when possible, and chemotherapy agents are chosen to minimize fetal exposure. Option A states 'Most common type is poly astrocytoma,' which is not a recognized standard term in modern neuro-oncology (the typical term is 'diffuse astrocytoma' or 'fibrillary astrocytoma'). Option B, stating that 'Surgical removal has good outcome,' reflects the principle that maximal safe resection is the cornerstone of management and is associated with improved survival and seizure control. Therefore, Option B is the better and correct answer. 1. Extent of surgical resection is the most important prognostic factor in low-grade gliomas. 2. Diffuse astrocytomas have an infiltrative pattern, which can lead to recurrence even after aggressive resection. 3. Molecular profiling (e.g., IDH mutation) is essential for prognosis and guiding therapy. Ongoing research focuses on the molecular underpinnings of low-grade gliomas, with IDH mutation status being one of the most prognostically significant markers. Recent guidelines emphasize individualized treatment planning and the potential role of early intervention with adjuvant therapies in cases with subtotal resection.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Infant with head 100 centile, height 10th centile, and weight 20th centile with multiple cafe au lait spots and axillary flickering. Diagnosis:",
    "option_a": "NF 1",
    "option_b": "NF 2",
    "option_c": "TSC",
    "option_d": "Fetal alcoholism syndrome",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Neurofibromatosis Type 1 (NF1) is an autosomal dominant neurocutaneous syndrome characterized by multiple caf\u00e9 au lait spots, axillary or inguinal freckling, and other features such as Lisch nodules and neurofibromas. It results from mutations in the NF1 gene which encodes the protein neurofibromin. The mutation in the NF1 gene leads to loss of function of neurofibromin, a tumor suppressor protein that normally helps regulate cell growth by inhibiting the Ras pathway. This loss predisposes individuals to the development of multiple benign and malignant tumors, as well as characteristic skin findings. Axillary freckling is a key diagnostic marker and, along with caf\u00e9 au lait spots, forms part of the NIH diagnostic criteria for NF1. In the infant described, the presence of multiple caf\u00e9 au lait spots and axillary freckling is pathognomonic for NF1. While NF1 may also be associated with macrocephaly, learning disabilities, and skeletal abnormalities, the skin findings are typically the earliest manifestations. The growth percentiles provided (head at 100th centile, height 10th centile, weight 20th centile) are not uncommon in NF1 and help differentiate it from other conditions. Diagnosis of NF1 is primarily clinical and is based on specific criteria (NIH diagnostic criteria). Differential diagnoses include Neurofibromatosis Type 2 (which presents with bilateral acoustic neuromas and lacks axillary freckling), Tuberous Sclerosis Complex (which primarily features ash-leaf spots, shagreen patches, and seizures), and the facial dysmorphism seen in fetal alcohol syndrome. Genetic testing can confirm the diagnosis in uncertain cases. Management of NF1 is multidisciplinary and primarily supportive, with emphasis on regular monitoring for complications such as optic pathway gliomas, plexiform neurofibromas, and learning disabilities. Annual ophthalmologic examinations and developmental assessments are recommended. In the context of pregnancy and lactation, NF1 does not preclude a safe pregnancy; however, monitoring for potential complications (such as tumor growth during pregnancy) is advised and requires coordination with neurology and obstetrics. Option A (NF1) is correct due to the classic presentation of multiple caf\u00e9 au lait spots and axillary freckling. Option B (NF2) is incorrect because it primarily features bilateral acoustic neuromas and lacks the skin findings described. Option C (TSC) is associated with hypomelanotic 'ash-leaf' spots rather than caf\u00e9 au lait spots, and Option D (Fetal alcoholism syndrome) does not typically present with these distinctive skin findings. 1. Axillary or inguinal freckling in combination with caf\u00e9 au lait spots is highly suggestive of NF1. 2. NF1 is an autosomal dominant condition with a wide spectrum of clinical manifestations. 3. Regular screening, especially in childhood, is important for early detection of complications such as optic pathway gliomas. Recent guidelines emphasize early diagnosis and multidisciplinary management of NF1. Advances in genetic testing and molecular research have improved our understanding of the NF1 mutation spectrum, informing both prognosis and the development of targeted therapies for certain complications of the disease.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "Patient came with brain tumor, hits first degree relative had history of spine tumor, persisting high BP. What is the diagnosis:",
    "option_a": "NF1",
    "option_b": "Familial schwannoma",
    "option_c": "Von-Hippel Lindau",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "C",
    "subspecialty": "Neuro-oncology",
    "explanation": "Von Hippel-Lindau (VHL) disease is an autosomal dominant disorder characterized by a predisposition to multiple tumors. In this scenario, the index patient\u2019s brain tumor, the history of a spinal tumor in a first\u2013degree relative, and persistent hypertension (often due to pheochromocytoma) strongly point toward VHL syndrome. VHL disease is caused by a mutation in the VHL tumor suppressor gene on chromosome 3, leading to impaired regulation of hypoxia-inducible factors. This results in neovascularization and the development of highly vascular tumors such as hemangioblastomas in the central nervous system, as well as other lesions like pheochromocytomas, renal cell carcinomas, pancreatic neuroendocrine tumors, and cysts. The association of persistent high blood pressure is explained by possible underlying pheochromocytoma. Clinically, patients with VHL present with retinal or cerebellar hemangioblastomas, sometimes with spinal cord involvement, along with endocrine manifestations. A family history of similar tumors reinforces the suspicion. The persistent high blood pressure in this patient is a clue to the possible presence of a pheochromocytoma, a common association with VHL. Differential diagnoses include Neurofibromatosis type 1 (characterized by caf\u00e9-au-lait spots, Lisch nodules, and neurofibromas) and familial schwannomatosis (multiple schwannomas, usually without vestibular involvement). The diagnosis of VHL is confirmed by comprehensive clinical evaluation, imaging studies (MRI for CNS lesions, CT for abdominal lesions) and genetic testing for VHL gene mutations. Management involves periodic whole\u2013body surveillance with MRI or CT scans to detect new lesions early. Symptomatic CNS hemangioblastomas may be managed with surgical resection or radiosurgery. Pheochromocytomas require medical stabilization (with alpha blockade followed by beta blockade) prior to surgical intervention. In pregnancy and lactation, imaging studies are preferably done using MRI without contrast and surgical interventions are timed appropriately to minimize risks to the fetus while managing maternal disease. Option A (NF1) is incorrect because NF1 is associated with caf\u00e9-au-lait spots and neurofibromas rather than the combination of CNS hemangioblastomas and pheochromocytoma seen here. Option B (Familial schwannoma) does not account for the endocrine component (persistent high BP) and the pattern of tumors described. Option C (Von Hippel-Lindau) correctly encompasses the constellation of findings. Option D is not provided. 1. Always suspect VHL in patients with CNS hemangioblastomas and a family history of similar tumors along with findings suggestive of pheochromocytoma. 2. Pheochromocytomas in VHL can cause persistent hypertension. 3. Genetic counseling and regular surveillance are critical in managing VHL. Recent guidelines emphasize the role of genetic screening and regular imaging surveillance in patients with VHL. Novel targeted therapies and refinement in radiosurgical techniques have also been incorporated into the management algorithms to improve long-term outcomes.",
    "exam_year": "2018",
    "exam_type": "Promotion"
  },
  {
    "question": "diffuse astrocytoma grade 2:",
    "option_a": "Pilocytic astrocytoma.",
    "option_b": "Has good response to resection.",
    "option_c": "",
    "option_d": "is not provided.",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "Von Hippel-Lindau (VHL) disease is an autosomal dominant disorder characterized by a predisposition to multiple tumors. In this scenario, the index patient\u2019s brain tumor, the history of a spinal tumor in a first\u2013degree relative, and persistent hypertension (often due to pheochromocytoma) strongly point toward VHL syndrome. VHL disease is caused by a mutation in the VHL tumor suppressor gene on chromosome 3, leading to impaired regulation of hypoxia-inducible factors. This results in neovascularization and the development of highly vascular tumors such as hemangioblastomas in the central nervous system, as well as other lesions like pheochromocytomas, renal cell carcinomas, pancreatic neuroendocrine tumors, and cysts. The association of persistent high blood pressure is explained by possible underlying pheochromocytoma. Clinically, patients with VHL present with retinal or cerebellar hemangioblastomas, sometimes with spinal cord involvement, along with endocrine manifestations. A family history of similar tumors reinforces the suspicion. The persistent high blood pressure in this patient is a clue to the possible presence of a pheochromocytoma, a common association with VHL. Differential diagnoses include Neurofibromatosis type 1 (characterized by caf\u00e9-au-lait spots, Lisch nodules, and neurofibromas) and familial schwannomatosis (multiple schwannomas, usually without vestibular involvement). The diagnosis of VHL is confirmed by comprehensive clinical evaluation, imaging studies (MRI for CNS lesions, CT for abdominal lesions) and genetic testing for VHL gene mutations. Management involves periodic whole\u2013body surveillance with MRI or CT scans to detect new lesions early. Symptomatic CNS hemangioblastomas may be managed with surgical resection or radiosurgery. Pheochromocytomas require medical stabilization (with alpha blockade followed by beta blockade) prior to surgical intervention. In pregnancy and lactation, imaging studies are preferably done using MRI without contrast and surgical interventions are timed appropriately to minimize risks to the fetus while managing maternal disease. Option A (NF1) is incorrect because NF1 is associated with caf\u00e9-au-lait spots and neurofibromas rather than the combination of CNS hemangioblastomas and pheochromocytoma seen here. Option B (Familial schwannoma) does not account for the endocrine component (persistent high BP) and the pattern of tumors described. Option C (Von Hippel-Lindau) correctly encompasses the constellation of findings. Option D is not provided. 1. Always suspect VHL in patients with CNS hemangioblastomas and a family history of similar tumors along with findings suggestive of pheochromocytoma. 2. Pheochromocytomas in VHL can cause persistent hypertension. 3. Genetic counseling and regular surveillance are critical in managing VHL. Recent guidelines emphasize the role of genetic screening and regular imaging surveillance in patients with VHL. Novel targeted therapies and refinement in radiosurgical techniques have also been incorporated into the management algorithms to improve long-term outcomes.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "what is the most common pediatric posterior fossa tumors:",
    "option_a": "Ependymoma- pilocytic astrocytoma - Medulloblastoma.",
    "option_b": "Meningioma...",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A",
    "subspecialty": "Neuro-oncology",
    "explanation": "Pediatric posterior fossa tumors are those that occur in the region of the cerebellum, brainstem, and fourth ventricle. The three tumors classically encountered in this region in children are medulloblastoma, pilocytic astrocytoma, and ependymoma. These tumors account for the majority of intracranial neoplasms in children, whereas meningiomas are rare in the pediatric population. Medulloblastomas are aggressive, high-grade embryonal tumors originating from the cerebellar granular cell layer; pilocytic astrocytomas, arising from astrocytes, are usually low-grade (WHO Grade I) and tend to have a cystic component with an enhancing mural nodule; ependymomas derive from the ependymal lining of the ventricles. All these tumors, due to their location in the confined space of the posterior fossa, can lead to obstructive hydrocephalus and subsequent raised intracranial pressure. Children with posterior fossa tumors typically present with symptoms of increased intracranial pressure such as headache, vomiting, and papilledema, as well as cerebellar signs like ataxia and coordination difficulties. The clinical presentation can vary depending on the specific tumor type and its location within the posterior fossa. The evaluation of pediatric posterior fossa tumors begins with neuroimaging, primarily MRI with and without contrast, which is essential for anatomical delineation and surgical planning. CT scans may be utilized in emergency settings. Definitive diagnosis is established by histopathological examination following surgical biopsy or resection. Differential diagnoses include brainstem glioma, cerebellar hemangioblastoma (in older children/adolescents, especially with von Hippel-Lindau syndrome), and even non-neoplastic processes like abscesses or arachnoid cysts. Management is tailored by tumor type. Complete surgical resection is the cornerstone for pilocytic astrocytoma, often leading to excellent outcomes. In medulloblastoma, maximal safe resection followed by adjuvant craniospinal irradiation and chemotherapy is standard; careful modification of radiation protocols is crucial in very young children to minimize neurocognitive side effects. Ependymomas are typically managed with aggressive surgical resection, sometimes followed by localized radiotherapy. In cases involving adolescent females who are pregnant or lactating, treatment protocols must be adjusted in accordance with current guidelines to minimize fetal or neonatal exposure; for example, delaying radiation or modifying chemotherapy regimens when possible. Option A lists the three most common pediatric posterior fossa tumors: ependymoma, pilocytic astrocytoma, and medulloblastoma, which is consistent with epidemiological data. Option B, which mentions meningioma, is incorrect because meningiomas are extremely rare in children. The absence of details in options C and D further supports the selection of Option A as the correct answer. \u2022 Rapid recognition and treatment of posterior fossa tumors are critical due to the risk of obstructive hydrocephalus and brainstem compression.  \u2022 While pilocytic astrocytomas are the most common benign tumor and medulloblastomas the most common malignant tumor in this region, ependymomas also represent a significant portion of cases.  \u2022 Multidisciplinary management, including neurosurgery, oncology, and radiation therapy, is necessary for optimal outcomes.  \u2022 In the rare instances of adolescent pregnancy, treatment plans must carefully balance maternal benefits with fetal and neonatal risks. Recent studies emphasize the role of molecular subtyping, particularly in medulloblastoma, to better predict prognosis and tailor therapy. Advances in imaging and surgical techniques have improved the extent of resection possible, which is critical for long-term outcomes, especially for pilocytic astrocytomas and ependymomas. Ongoing clinical trials and updated treatment protocols continue to assess the reduction of radiation doses and chemotherapeutic regimens in pediatric populations to minimize long-term neurocognitive impact while preserving oncologic efficacy.",
    "exam_year": "2019",
    "exam_type": "Promotion"
  },
  {
    "question": "59 y.o male Patient k/c of prostatic cancer present to you picture attached attached ?",
    "option_a": "hemorragic mets",
    "option_b": "amyloid angiopathy",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuro-oncology",
    "explanation": "This question requires distinguishing the cause of an intracerebral hemorrhage seen on imaging. Although the patient\u2019s history of prostate cancer might prompt one to consider a hemorrhagic metastasis, the imaging characteristics must be matched with the typical pathology. In this context, even in a patient with a known malignancy, one must not be misled if the hemorrhage shows a classic lobar pattern consistent with cerebral amyloid angiopathy. Cerebral amyloid angiopathy (CAA) is caused by the deposition of \u03b2-amyloid protein in the walls of small-to-medium cortical and leptomeningeal arteries. This process weakens the vessel walls, predisposing them to rupture, and typically leads to lobar (cortical-subcortical) hemorrhages. This is mechanistically different from hemorrhagic metastases, which occur when tumor deposits invade cerebral vasculature and cause vessel disruption, a phenomenon more typical of melanomas, renal cell carcinomas, or choriocarcinomas rather than prostate cancer. Patients with CAA often present with spontaneous, sometimes recurrent, lobar hemorrhages. Although the patient is 59 years old (borderline for what is classically considered an elderly patient), the imaging findings (presumed to show a cortical or subcortical, lobar bleed) are more in keeping with CAA than with metastatic disease. Prostate cancer rarely metastasizes to the brain, and when it does, the lesions generally do not present with the typical hemorrhagic pattern seen in CAA. The diagnostic work-up would include a non-contrast CT scan to identify the location and extent of the hemorrhage. MRI with gradient-echo or susceptibility weighted imaging (SWI) sequences is particularly useful to detect multiple microbleeds; a lobar distribution of these microbleeds supports the diagnosis of CAA. Differential diagnoses to consider include hypertensive hemorrhage (which tends to affect deep brain structures like the basal ganglia or thalamus) and hemorrhagic metastases (which might show a mass with surrounding vasogenic edema in a patient with cancers that commonly metastasize to the brain). Management of CAA is generally supportive. This includes aggressive blood pressure control to minimize the risk of rebleeding, seizure prophylaxis if indicated, and cautious use of antithrombotic agents (bearing in mind that antiplatelet and anticoagulant therapies can increase risk). In patients who are pregnant or lactating, antihypertensives with established safety profiles (e.g., labetalol) are preferred, and imaging modalities should be chosen to minimize fetal exposure when necessary. In contrast, if the hemorrhage were due to metastasis, treatment might involve a neurosurgical evaluation, stereotactic radiosurgery, or whole brain radiotherapy, alongside systemic cancer management. Option A (hemorrhagic mets) might be considered in patients with hypervascular tumors known to metastasize to the brain; however, prostate cancer is a rare source of brain metastases and typically does not present with hemorrhage. Option B (amyloid angiopathy) is more consistent with the presumed lobar hemorrhage pattern seen on imaging. Thus, despite the history of prostatic cancer, the imaging appearance leads to the diagnosis of CAA, validating Option B. \u2022 Do not let a patient\u2019s cancer history automatically shift the diagnosis toward metastasis\u2014correlate the imaging pattern with the most likely etiology.  \u2022 CAA typically causes lobar hemorrhages, often best visualized on MRI as cortical microbleeds, and is relatively uncommon in patients with deep (basal ganglia or thalamic) bleeds.  \u2022 Prostate cancer rarely metastasizes to the brain; hemorrhagic brain metastases are more typical of melanomas, renal cell carcinoma, and choriocarcinoma. Recent neuroimaging guidelines emphasize the role of MRI (with GRE/SWI sequences) in diagnosing CAA by detecting a characteristic pattern of lobar microbleeds. The latest evidence also stresses careful blood pressure management and a cautious approach to antithrombotic therapy in patients with CAA, including considerations for those who are pregnant or lactating, where medication selection must consider fetal and neonatal safety profiles.",
    "exam_year": "2021",
    "exam_type": "Promotion"
  }
]